EYPT SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving EyePoint Pharmaceuticals
SueWallSt.com has announced an investigation into EyePoint Pharmaceuticals (NASDAQ: EYPT) following a significant 67% stock drop after its DURAVYU drug failed to meet its primary endpoint in a Phase 3 trial for wet AMD. The firm is inviting investors who suffered losses to submit their information for a potential securities fraud claim, questioning whether EyePoint made misleading statements about the trial's progress. This investigation highlights concerns about the company's prior assurances regarding the drug's potential before disclosing the trial's failure.
Eyepoint Pharmaceuticals (NASDAQ:EYPT) Downgraded by Royal Bank Of Canada to "Hold"
Royal Bank of Canada downgraded Eyepoint Pharmaceuticals (NASDAQ:EYPT) from "moderate buy" to "hold," and Cantor Fitzgerald also shifted to a neutral rating. This follows the company's DURAVYU trial missing its primary endpoint, leading to a sharp stock decline and concerns about its future regulatory and commercial success. Despite some analysts maintaining "buy" ratings, the consensus among analysts tracked by MarketBeat is now "Hold" with an average price target of $28.11.
EYPT Stock Crashes On Duravyu Data But Catalysts Loom
EyePoint Pharmaceuticals (EYPT) stock initially crashed by 69% after its Phase 3 LUGANO trial for DURAVYU in wet AMD missed its primary vision endpoint on the full dataset. However, an ad hoc analysis, excluding an asymmetric cohort, showed non-inferiority against aflibercept and other strong secondary outcomes, leading to a rebound. Despite a wider Q2 EPS loss, the company has significant cash reserves and upcoming catalysts, including topline data for the LUCIA trial in Q4 2026 and potential NDA submission in 2027.
Citigroup Issues Pessimistic Forecast for Eyepoint Pharmaceuticals (NASDAQ:EYPT) Stock Price
Citigroup has significantly cut its price target for Eyepoint Pharmaceuticals (NASDAQ:EYPT) from $35.00 to $17.00, while still maintaining a "buy" rating, indicating a potential upside of 216.10% from its current price of $5.38. This downgrade follows the failure of the company's LUGANO trial for DURAVYU to meet its primary endpoint and a reported quarterly loss of $1.09 per share, missing consensus estimates. The stock has seen a sharp decline, trading near its one-year low, and analysts' consensus for EYPT is now a "Hold" with an average target of $28.11.
Eyepoint Pharmaceuticals' (EYPT) Sector Perform Rating Reiterated at Royal Bank Of Canada
Royal Bank of Canada reiterated its "sector perform" rating for EyePoint Pharmaceuticals (EYPT) but significantly cut its price target to $5 from $37, citing uncertainty after the DURAVYU Phase 3 LUGANO trial missed its primary endpoint. Despite this, other analysts remain divided, with some maintaining "buy" ratings and higher price targets, while the company’s stock price opened at $4.87. The company's Q2 earnings missed analyst estimates, and institutional investors have recently adjusted their holdings in EYPT.
HC Wainwright Downgrades EyePoint Pharmaceuticals to Neutral From Buy
HC Wainwright has downgraded EyePoint Pharmaceuticals from Buy to Neutral. This follows similar downgrades from other firms like RBC Capital Markets and Chardan, driven by the company's DURAVYU drug failing its primary goal in a Phase 3 wet AMD trial. The downgrades reflect increasing regulatory uncertainty and a significantly reduced average target price for EyePoint.
The Surprising Reason This Biotech Just Plummeted 67%
EyePoint (EYPT) stock plummeted by 67% after its eye disease treatment, Duravyu, failed to meet its primary goal in a final-phase study for wet age-related macular degeneration. Despite lowering treatment burden and a significant percentage of patients being supplement-free, the drug's inability to achieve its main objective led to a sharp decline in the company's stock value. This unexpected failure highlights the high-risk nature of biotech investments tied to drug trial outcomes.
EyePoint Announces Topline Data from LUGANO, the First of Two Pivotal Phase 3 Clinical Trials for DURAVYU™ 2.7mg in Wet AMD
EyePoint, Inc. announced topline data from its LUGANO Phase 3 clinical trial for DURAVYU™ (vorolanib intravitreal insert) in wet AMD. While the primary endpoint of change in best corrected visual acuity was not met in the full dataset due to an asymmetric cohort experiencing vision loss unrelated to wet AMD, DURAVYU demonstrated non-inferiority in an ad hoc analysis and showed significant improvements in key secondary endpoints such as treatment burden reduction and high supplement-free rates. EyePoint anticipates filing a New Drug Application in the first half of 2027, pending results from the second Phase 3 trial, LUCIA, expected in Q4 2026.
NKE, META, IVF, EYPT, MU: 5 Trending Stocks Today - Micron Technology (NASDAQ:MU)
Major U.S. indices closed lower, but several individual stocks saw significant movement. Nike (NKE) hit a 52-week low due to concerns in the athletic-wear market, and Meta Platforms (META) declined amid legal challenges and AI strategy uncertainties. Conversely, INVO Fertility (IVF) surged after reporting strong Q2 results, while EyePoint (EYPT) plummeted due to mixed Phase 3 clinical trial data. Micron Technology (MU) rose on optimistic analyst projections regarding AI-driven demand and free cash flow potential.
Nike, Meta Platforms, INVO Fertility, EyePoint Pharmaceuticals, and Micron: Why These 5 Stocks Are on Investors' Radars Today
This article highlights five stocks that captured investor attention on Monday, August 17th, with varied performances. Nike and Meta Platforms experienced declines due to market concerns and legal challenges respectively. In contrast, INVO Fertility saw a significant surge after beating EPS expectations, while EyePoint Pharmaceuticals plummeted due to mixed Phase 3 clinical trial results. Micron Technology rose on optimistic analyst projections driven by AI-fueled demand for memory.
Eyepoint Pharmaceuticals (NASDAQ:EYPT) Hits New 12-Month Low Following Analyst Downgrade
Eyepoint Pharmaceuticals (NASDAQ:EYPT) shares dropped to a new 52-week low after Jefferies Financial Group lowered its price target to $8, although maintaining a "buy" rating. This follows the failure of the DURAVYU trial to meet its primary endpoint, raising concerns about the drug's approval despite an adjusted analysis showing non-inferiority to aflibercept. Analyst sentiment is mixed, with a consensus "Moderate Buy" rating, but some firms like Cantor Fitzgerald downgraded the stock to "neutral."
EyePoint Blames Asymmetry For Phase III Trial Failure In Wet AMD
EyePoint Pharmaceuticals reported a failure in its Phase III trial for a wet AMD treatment, attributing it to an "asymmetry" caused by nine patients with pre-existing vision-threatening conditions unrelated to wet AMD. These conditions, including geographic atrophy, glaucoma, and retinal detachment, confounded the primary endpoint results. The company cites these pre-existing issues as the reason for the trial's unsuccessful outcome.
EyePoint Stock Craters 69% After Drug Trial Failure. It May Be an Overreaction.
EyePoint Pharmaceuticals (EYPT) shares plummeted by 69% after its lead pipeline candidate, Duravyu, missed primary endpoints in two Phase 3 trials for a severe eye disease. Despite management calling the results "clinically meaningful," the market reacted strongly to the trial failure. The article suggests this significant drop might be an overreaction, hinting at potential value in the company post-crash.
EyePoint's Duravyu misses wet AMD primary endpoint, hinges on second trial for FDA path
EyePoint Pharmaceuticals announced that its drug vorolanib (Duravyu) failed to meet the primary endpoint in the LUGANO Phase III trial for wet age-related macular degeneration (wet AMD), as it did not demonstrate non-inferiority to aflibercept. Despite this setback, the program's FDA path now heavily relies on the results of a second pivotal trial, LUCIA, expected in Q4 2026, due to favorable treatment-burden and safety data from LUGANO. Duravyu aims to offer a six-month dosing interval for wet AMD patients using an office-based, bioerodible intravitreal insert.
EyePoint’s DURAVYU Misses Primary Endpoint in Phase III Wet AMD Trial
EyePoint Pharmaceuticals announced that its drug DURAVYU failed to meet the primary non-inferiority endpoint in the Phase III LUGANO trial for wet Age-related Macular Degeneration (AMD). The company attributed the miss to nine patients who experienced significant vision loss from conditions unrelated to wet AMD, and an ad hoc analysis excluding these patients did show non-inferiority. Despite this setback, EyePoint remains optimistic about its ongoing LUCIA trial and plans to pursue FDA approval in early 2027 if those results are positive.
Cantor Fitzgerald Downgrades Eyepoint Pharmaceuticals (NASDAQ:EYPT) to Neutral
Cantor Fitzgerald downgraded Eyepoint Pharmaceuticals (NASDAQ:EYPT) from an "overweight" to a "neutral" rating, causing shares to fall by $10.59 to $4.16, near its 52-week low. Despite the downgrade, the consensus among analysts remains a "Moderate Buy" with a target price of $44.38. The company reported a quarterly loss that missed estimates but exceeded revenue expectations.
EYPT Stock Slips As Insider Plans Share Sale
EyePoint Pharmaceuticals (EYPT) stock has dropped significantly following news of an insider's plan to sell securities, as indicated by an amended Form 144/A filing. While the company has a strong balance sheet with substantial cash reserves and a recent multi-week price climb, the insider selling has introduced short-term risk and volatility. Traders are now focusing on price action and risk management due to this shift in sentiment.
EYPT Maintains Buy Rating by Chardan Capital -- Price Target Set at $65
Chardan Capital maintained its Buy rating for EyePoint Pharmaceuticals (EYPT) with a price target of $65.00, despite the stock being significantly overvalued according to GuruFocus's GF Value™ of $0.36 versus its current price of $14.76. The company also received a low GF Score™ of 34/100, indicating significant concerns about financial health, profitability, and growth potential, further complicated by insider selling and mixed guru sentiment. Investors are advised to proceed with caution due to the overvaluation and financial weaknesses.
Eyepoint Pharmaceuticals stock hits 52-week low at $4.06 By Investing.com
Eyepoint Pharmaceuticals Inc. (EYPT) stock recently hit a 52-week low of $4.06, despite a 33% increase over the past year. Analysts maintain a bullish outlook with an average price target suggesting a 58% upside. The company recently announced stockholder approval for an increase in authorized shares and the election of new directors, while Mizuho and Stifel have raised price targets based on trial outlook and the potential of its retinal disease treatment, Duravyu.
Form 8K Eyepoint Pharmaceuticals Inc For: 17 August By Investing.com
This article reports on the filing of a Form 8K by Eyepoint Pharmaceuticals Inc. on August 17th. The brief piece includes the stock symbol EYPT, which is noted to be down 68.88%. No further details about the content of the Form 8K are provided.
EYPT Looks 4000.0% Overvalued on GF Value™
EyePoint Pharmaceuticals (EYPT) is considered 4000.0% overvalued based on GuruFocus's GF Value™ metric, trading at $14.76 against an estimated fair value of $0.36. This extreme valuation comes despite its Duravyu wet AMD trial showing mixed results—failing the primary endpoint in the overall dataset but succeeding in secondary outcomes like reducing treatment burden. The company's GF Score™ is low at 34/100 due to weak profitability and growth, but it maintains moderate financial strength and momentum, with investor optimism focused on its pipeline potential.
Eyepoint Pharmaceuticals (NASDAQ:EYPT) Given "Buy" Rating at Chardan Capital
Chardan Capital has reiterated a "Buy" rating for Eyepoint Pharmaceuticals (NASDAQ:EYPT) with a price target of $65.00, suggesting a significant upside. The company reported a quarterly loss of $1.09 per share, missing estimates, but revenue exceeded expectations. Institutional investors hold a substantial 99.41% stake in the company.
EyePoint’s DURAVYU misses primary endpoint in wet AMD trial
EyePoint, Inc. announced that its Phase 3 LUGANO trial for DURAVYU in wet AMD treatment failed to meet its primary endpoint, largely due to an asymmetric cohort of patients experiencing vision loss unrelated to wet AMD. Despite this, an ad hoc analysis showed non-inferiority to aflibercept and the drug met several secondary endpoints, including a significant reduction in treatment burden. The company anticipates topline data from its second pivotal trial, LUCIA, in Q4 2026.
EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
EyePoint, Inc. announced that it granted non-statutory stock options to two new employees as inducement awards under NASDAQ Listing Rule 5635(c)(4). These options allow purchase of up to 14,600 shares of common stock with an exercise price of $14.75 per share, vesting over four years. This action is part of the company's commitment to developing therapeutics for serious retinal diseases.
EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
EyePoint, Inc. announced the granting of non-statutory stock options to two new employees as inducement awards, in accordance with NASDAQ Listing Rule 5635(c)(4). These options allow the purchase of up to 14,600 shares of common stock, with an exercise price of $14.75 per share, and vest over four years. This action is part of the company's efforts to attract talent to support its development of therapeutics for serious retinal diseases.
EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
EyePoint, Inc. announced inducement grants of non-statutory stock options to two new employees for an aggregate of 14,600 shares of common stock. These grants were approved by the Compensation Committee and made in accordance with NASDAQ Listing Rule 5635(c)(4) to induce their employment. The options have an exercise price of $14.75 per share, a ten-year term, and vest over four years.
Eyepoint Pharmaceuticals, Inc. $EYPT Stock Position Boosted by California State Teachers Retirement System
The California State Teachers Retirement System significantly increased its stake in Eyepoint Pharmaceuticals (NASDAQ:EYPT) by 2,158.3% in the first quarter, now holding 105,101 shares. Several other institutional investors also adjusted their positions in the company. Despite missing earnings per share estimates, Eyepoint Pharmaceuticals exceeded revenue expectations, and analysts generally maintain a "Moderate Buy" rating with a target price of $44.38.
Stock Traders Purchase Large Volume of Eyepoint Pharmaceuticals Put Options (NASDAQ:EYPT)
Traders recently purchased a significantly higher volume of Eyepoint Pharmaceuticals (NASDAQ:EYPT) put options, indicating increased bearish sentiment or hedging activity. This comes after the company missed its quarterly EPS expectations, reporting a loss of $1.09 per share against an expected $1.01 loss. Despite the unusual put option activity and weaker earnings, Wall Street analysts maintain a "Moderate Buy" consensus rating with an average price target significantly above the current trading price.
EyePoint Pharmaceuticals, Inc. (EYPT) options chain
This article provides detailed options chain data for EyePoint Pharmaceuticals, Inc. (EYPT) for the contract date of October 16, 2026. It lists various call and put options, including strike prices, last trade dates, last prices, implied volatility, and other relevant trading metrics. The information reflects the stock's performance at market close and after hours on August 13, 2026.
Eyepoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Receives Average Recommendation of "Moderate Buy" from Brokerages
Eyepoint Pharmaceuticals (NASDAQ:EYPT) has received a "Moderate Buy" consensus rating from nine brokerages, with an average 12-month price target of $44.38. Institutional ownership is high at 99.41%, with several major firms recently increasing their stakes. Despite positive analyst sentiment regarding its pipeline, the company continues to face financial losses, reporting a quarterly loss wider than estimates and projected full-year losses.
Trading the Move, Not the Narrative: (EYPT) Edition
This article provides a detailed AI-driven analysis for Eyepoint Pharmaceuticals Inc. (EYPT), highlighting divergent sentiment readings and outlining specific trading strategies for various risk profiles. It identifies key support and resistance levels across multiple timeframes and suggests a significant risk-reward short setup. The analysis emphasizes trading based on market moves rather than narratives, using advanced AI models.
EyePoint Pharma nears key Phase III data for DURAVYU in wet AMD, aiming to reduce injection frequency by 2026
EyePoint Pharmaceuticals is awaiting crucial Phase III LUGANO trial results for its wet AMD treatment, DURAVYU, which are expected by August 2026. The trial is designed to show sustained six-month dosing and compares directly to existing standard treatments. EyePoint's strong market position is bolstered by its manufacturing infrastructure and drug delivery platform, with a cash runway extending to late 2027, though positive trial data will be key for future funding.
Eyepoint Pharmaceuticals' (EYPT) "Buy" Rating Reiterated at Chardan Capital
Chardan Capital has reiterated its "Buy" rating for Eyepoint Pharmaceuticals (NASDAQ:EYPT) and set a $65 price target, indicating a potential upside of over 400%. Despite a recent quarterly loss that missed analyst estimates, the company's revenue exceeded expectations, and institutional investors hold a significant majority of its stock. Analyst sentiment remains generally positive, with a "Moderate Buy" consensus rating.
RBC Capital Keeps Their Buy Rating on EyePoint Pharmaceuticals (EYPT)
RBC Capital analyst Lisa Walter reiterated a Buy rating for EyePoint Pharmaceuticals (EYPT) with a price target of $37.00. This comes despite a GAAP net loss of $84.83 million in the latest quarter and negative insider sentiment with increased selling of shares. H.C. Wainwright also maintained a Buy rating, though with a lower price target of $27.00.
Eyepoint Pharmaceuticals (NASDAQ:EYPT) Given New $55.00 Price Target at Cantor Fitzgerald
Cantor Fitzgerald has increased its price target for Eyepoint Pharmaceuticals (NASDAQ:EYPT) to $55.00 from $47.00, maintaining an "overweight" rating and suggesting a substantial upside. This new target is part of generally positive analyst sentiment, even as the company recently reported a quarterly EPS loss that missed estimates, despite revenue exceeding expectations. Institutional investors hold a significant portion of the company's stock, reflecting strong investor interest.
EyePoint Pharmaceuticals Inc (EYPT) Earnings Forecast: Future EPS & Revenue Growth Estimates
This article provides an earnings forecast for EyePoint Pharmaceuticals Inc (EYPT), highlighting its current earnings forecast score of 8.71 within the Pharmaceuticals industry. It details analyst ratings, price targets, and expected EPS and revenue figures. The forecast indicates a "Buy" trend based on analyst consensus, with a target price of $33.00.
EYPT Maintained by Cantor Fitzgerald -- Price Target Raised to $55
Cantor Fitzgerald maintained an Overweight rating for EyePoint Pharmaceuticals (EYPT) and raised its price target from $47.00 to $55.00, signaling a positive outlook despite the company's current overvaluation according to GuruFocus. EYPT's GF Value™ indicates it is significantly overvalued at $0.69 compared to its current price of $12.24, and its GF Score™ of 35/100 highlights weaknesses in profitability and growth. Insider activity shows net selling, further complicating the investment thesis despite the analyst's optimism.
EyePoint, Inc. (EYPT) Stock Price, News, Quote & History
This article provides a comprehensive overview of EyePoint, Inc. (EYPT), a biotechnology company specializing in therapeutics for retinal diseases. It includes current stock price, historical performance data, key financial metrics, and analyst ratings. The company is developing treatments like DURAVYU and EYP-2301, leveraging its proprietary Durasert E technology for sustained intraocular drug delivery.
Ahead‑of‑Schedule DME Trial Enrollment Could Be A Game Changer For EyePoint (EYPT)
EyePoint Pharmaceuticals has completed enrollment ahead of schedule for its Phase 3 trials of DURAVYU for diabetic macular edema (DME), enrolling over 480 patients in five months. This rapid progress, coupled with favorable safety data, suggests DURAVYU could be a significant long-acting treatment option in the retinal disease market. The development tightens EyePoint's timelines and improves its risk profile, although upcoming wet AMD Phase 3 readouts remain the primary catalyst and risk factor.
Ahead‑of‑Schedule DME Trial Enrollment Could Be A Game Changer For EyePoint (EYPT)
EyePoint Pharmaceuticals has completed enrollment ahead of schedule for its Phase 3 trials of DURAVYU for diabetic macular edema (DME), enrolling over 480 patients in five months. This rapid enrollment, coupled with prior safety data and regulatory alignment, positions DURAVYU as a potential long-acting treatment in the retinal disease market. The development strengthens EyePoint's investment narrative by reducing timeline risks, though wet AMD Phase 3 readouts remain the primary catalyst, and the company's cash runway and spending continue to be significant factors for investors.
EyePoint Pharmaceuticals Inc (EYPT) News, Articles, Events & Latest Updates
This article provides recent news and updates on EyePoint Pharmaceuticals Inc (EYPT), including its Q2 and Q1 earnings performance, analyst ratings, and insider stock transactions. It highlights EyePoint's financial results, such as beating revenue estimates in Q2 and Q1 2026, and mentions analyst consensus rating the stock as "Buy." The article also notes an insider sale of EYPT stock.
Eyepoint Pharma earnings on deck ahead of pivotal trial data
Eyepoint Pharmaceuticals Inc. is set to report Q2 earnings, with investors keenly anticipating updates on its pivotal Phase 3 LUGANO trial for Duravyu, a treatment for wet age-related macular degeneration. Analysts expect a narrower loss and lower revenue, but focus remains on the trial data release in August 2026, which is seen as a major catalyst. Concerns regarding cash runway and competitive positioning in the crowded retinal disease market will also be closely watched.
Earnings Flash (EYPT) EyePoint, Inc. Reports Q2 Revenue $507,000, vs. FactSet Est of $390,000
EyePoint, Inc. (EYPT) reported second-quarter revenue of $507,000, surpassing the FactSet estimate of $390,000. The company is a clinical-stage biopharmaceutical firm focused on developing treatments for serious retinal diseases, with its lead product candidate, DURAVYU, currently in Phase III pivotal trials for wet age-related macular degeneration and diabetic macular edema. Recent news includes updates on its clinical trials and several analyst rating changes.
EyePoint Q2 2026 earnings: Phase 3 spending widens the net loss
EyePoint (Nasdaq: EYPT) reported a widened diluted loss per share of $1.09 in Q2 2026, compared to $0.85 a year earlier, primarily due to increased spending on DURAVYU Phase 3 trials and manufacturing scale-up. Revenue significantly decreased to $0.5 million from $5.3 million, reflecting a prior-year deferred revenue recognition. The company's cash and investments declined to $180 million, but are expected to fund operations into Q4 2027, extending beyond the anticipated wet AMD data readouts later in 2026.
EYPT Looks 1591.3% Overvalued on GF Value™
EyePoint Pharmaceuticals (EYPT) is considered 1591.3% overvalued according to its GF Value™, primarily due to an extraordinary Price-to-Sales ratio of 111.19x, significantly higher than its historical median. The company, a clinical-stage biotech specializing in retinal disease treatments, is awaiting pivotal Phase 3 trial results for Duravyu, which is driving investor interest despite ongoing losses and a low GF Score™ of 35/100. While some institutional gurus are accumulating shares, insider selling suggests caution.
Eyepoint Pharma earnings on deck ahead of pivotal trial data By Investing.com
Eyepoint Pharmaceuticals Inc. is set to release its second-quarter earnings, with investor attention primarily focused on any updates regarding its pivotal Phase 3 LUGANO trial data for Duravyu, expected in August 2026. While analysts anticipate a loss of 95 cents per share on revenue of $400,900, the company's future hinges on the clinical trial results for its wet age-related macular degeneration treatment. Wall Street analysts maintain a strong buy rating with a consensus price target of $40.50, highlighting the significant potential upside if the trial data is positive.
Eyepoint Pharma earnings on deck ahead of pivotal trial data
Eyepoint Pharmaceuticals Inc. is set to report second-quarter earnings, with investor attention primarily focused on updates regarding its pivotal Phase 3 LUGANO trial for wet age-related macular degeneration, expected to release data in August 2026. Analysts maintain a "strong buy" rating with significant upside potential, driven by the experimental therapy Duravyu and its differentiated mechanism. The report will also shed light on cash runway, competitive positioning, and regulatory strategy for its clinical trials.
EyePoint Pharmaceuticals Inc (EYPT) Risk Assessment: Volatility, Financial Risk & Investment Risk
This article provides a risk assessment for EyePoint Pharmaceuticals Inc (EYPT), highlighting its current risk score of 4.82, which ranks it 80th out of 155 in the Pharmaceuticals industry. The company's beta of 1.74 indicates higher volatility compared to the S&P 500. The report details various metrics including VaR, maximum drawdown, volatility, Sharpe Ratio, and liquidity.
Eyepoint Pharmaceuticals (EYPT) to Announce Quarterly Earnings on Wednesday
Eyepoint Pharmaceuticals (EYPT) is scheduled to announce its Q2 2026 earnings before market open on Wednesday, August 5th. Analysts anticipate a loss of $0.92 per share and revenue of $0.387 million. Despite missing previous earnings estimates, the stock holds a "Moderate Buy" consensus rating with an average price target of $43.75, and institutional investors own 99.41% of its shares.
EyePoint Completes Enrollment in Phase 3 Duravyu Trials for DME Ahead of Schedule
EyePoint Pharmaceuticals has completed patient enrollment in its two global phase 3 clinical trials, COMO and CAPRI, for Duravyu (vorolanib intravitreal insert) to treat diabetic macular edema (DME), ahead of schedule. Over 480 patients were enrolled in five months, and topline results for efficacy and safety are anticipated in the fourth quarter of 2027. The studies compare Duravyu's 6-month dosing with aflibercept, building on positive Phase 2 VERONA trial outcomes.
